Universal Biosensors, Inc.

ASX:UBI Stock Report

Market Cap: AU$21.8m

Universal Biosensors Management

Management criteria checks 2/4

Universal Biosensors' CEO is John Sharman, appointed in Jan 2020, has a tenure of 5.17 years. total yearly compensation is A$883.80K, comprised of 58.3% salary and 41.7% bonuses, including company stock and options. directly owns 0.69% of the company’s shares, worth A$150.30K. The average tenure of the management team and the board of directors is 3.5 years and 5.9 years respectively.

Key information

John Sharman

Chief executive officer

AU$883.8k

Total compensation

CEO salary percentage58.3%
CEO tenure5.2yrs
CEO ownership0.7%
Management average tenure3.5yrs
Board average tenure5.9yrs

Recent management updates

Recent updates

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Dec 11
We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Nov 09
We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

May 03
We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Jan 12
We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Oct 10
We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth

Apr 28
Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

May 13
We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?

Feb 24
Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

Jan 20
We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More

Dec 15
The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More

CEO Compensation Analysis

How has John Sharman's remuneration changed compared to Universal Biosensors's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

-AU$14m

Sep 30 2024n/an/a

-AU$12m

Jun 30 2024n/an/a

-AU$12m

Mar 31 2024n/an/a

-AU$6m

Dec 31 2023AU$884kAU$515k

-AU$7m

Sep 30 2023n/an/a

-AU$18m

Jun 30 2023n/an/a

-AU$20m

Mar 31 2023n/an/a

-AU$26m

Dec 31 2022AU$532kAU$483k

-AU$27m

Sep 30 2022n/an/a

-AU$19m

Jun 30 2022n/an/a

-AU$16m

Mar 31 2022n/an/a

-AU$14m

Dec 31 2021AU$3mAU$480k

-AU$11m

Sep 30 2021n/an/a

-AU$7m

Jun 30 2021n/an/a

-AU$6m

Mar 31 2021n/an/a

-AU$8m

Dec 31 2020AU$696kAU$271k

-AU$8m

Compensation vs Market: John's total compensation ($USD554.59K) is above average for companies of similar size in the Australian market ($USD286.83K).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Sharman (58 yo)

5.2yrs

Tenure

AU$883,796

Compensation

Mr. John Stewart Sharman, M.App.Fin, CA, BEcon has been the Chief Executive Officer at Universal Biosensors, Inc. since 2020 and serves as its Director since January 15, 2025. He serves as Managing Directo...

Leadership Team

NamePositionTenureCompensationOwnership
John Sharman
MD, CEO & Director5.2yrsAU$883.80k0.69%
A$ 150.3k
Salesh Balak
Company Secretary & Corporate Advisor6.3yrsAU$366.11k0.13%
A$ 28.4k
Peter Mullin
Finance Directorless than a yearno data0.85%
A$ 185.5k
Nicholas Bliesner
Head of Operations3.8yrsno datano data
Keith Sims
Global Marketing Director1.2yrsno datano data
Anthony Soha
Head of Sales1.2yrsno datano data
Luke Cossins
Head of Research & Development4.2yrsno datano data
Ann Chew
Head of People Strategy & Culture3.2yrsno datano data

3.5yrs

Average Tenure

Experienced Management: UBI's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Sharman
MD, CEO & Directorless than a yearAU$883.80k0.69%
A$ 150.3k
Peter Mullin
Finance Directorless than a yearno data0.85%
A$ 185.5k
Craig Coleman
Non-Executive Director8.8yrsAU$86.40k0.33%
A$ 70.9k
David Hoey
Independent Non-Executive Director9yrsAU$77.60k0.22%
A$ 48.4k
Judith Smith
Independent Non-Executive Director10yrsAU$85.94k0.15%
A$ 32.3k
Graham McLean
Independent Non-Executive Chairman3yrsAU$111.33k0.36%
A$ 78.8k
David Church
Member of the Scientific Advisory Panelno datano datano data
John Loftus
Member of the Scientific Advisory Panelno datano datano data
Simon Corrie
Member of the Scientific Advisory Panelno datano datano data
Steve Kitchen
Member of the Scientific Advisory Panelno datano datano data
Sam Schulman
Member of the Scientific Advisory Panelno datano datano data
Davide Matino
Member of the Scientific Advisory Panelno datano datano data

5.9yrs

Average Tenure

59yo

Average Age

Experienced Board: UBI's board of directors are considered experienced (5.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/22 07:22
End of Day Share Price 2025/03/18 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Universal Biosensors, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tara SperanzaBell Potter
Shane StoreyWilsons Advisory and Stockbroking Ltd.